

	Rosiglitazone maleate in MeOH at λ_{\max} =246.8 nm	
4.17	Mean absorbance values, regressed values and statistical data of the calibration curve for the estimation of Rosiglitazone base in ACN-PBS (pH 7.4) at λ_{\max} =246.2 nm	128
4.18	Intra-day accuracy and precision of calibration curve of Rosiglitazone base in ACN-PBS (pH 7.4) at λ_{\max} =246.2 nm	129
4.19	Inter-day accuracy and precision of calibration curve of Rosiglitazone base in ACN-PBS (pH 7.4) at λ_{\max} =246.2 nm	129
5.1	Optimization of formulation parameters for Pioglitazone formulations prepared by nanoprecipitation method	141
5.2	Optimization of formulation parameters for Rosiglitazone formulations prepared by nanoprecipitation method	142
5.3	Optimization of formulation parameters for Pioglitazone formulations prepared by emulsion solvent evaporation method	151
5.4	Optimization of formulation parameters for Rosiglitazone formulations prepared by emulsion solvent evaporation method	152
5.5	Particle size, PDI, entrapment efficiency and zeta potential data of optimized drug (Pioglitazone/Rosiglitazone) loaded NPs formulations	167
5.6	Drug content of Pioglitazone/Rosiglitazone in their nasal solution	167
5.7	The kinetic parameters for release of Pioglitazone from PIO-NP nanoparticles in PBS (pH 7.4)	167
5.8	The kinetic parameters for release of Pioglitazone from Tf-PIO-NP nanoparticles in PBS (pH 7.4)	168
5.9	The kinetic parameters for release of Rosiglitazone from ROS-NP nanoparticles in PBS (pH 7.4)	168
5.10	The kinetic parameters for release of Rosiglitazone from Tf-ROS-NP nanoparticles in PBS (pH 7.4)	169
5.11	Effect of different cryoprotectants on the particle size and redispersability of PLGA nanoparticles	169
6.1	Effect on appearance of optimized formulations of Pioglitazone and Rosiglitazone at $5^{\circ}\text{C}\pm 2^{\circ}\text{C}$ during 6 months storage.	209
6.2	Effect on appearance of optimized formulations of Pioglitazone and Rosiglitazone at $25^{\circ}\text{C}\pm 2^{\circ}\text{C}$ at $60\pm 5\%$ RH during 6 months storage.	209
6.3	Effect on particle size and PDI of optimized nanoparticulate formulations of Pioglitazone and Rosiglitazone during 6	210

	months storage.	
6.4	Effect on zeta potential of optimized nanoparticulate formulations of Pioglitazone and Rosiglitazone during 6 months storage.	211
6.5	Effect on drug content of optimized nanoparticulate formulations of Pioglitazone and Rosiglitazone during 6 months storage.	212
7.1	Hemolytic profile of PIO & ROS and their formulations	229
7.2	Cytoprotective study of various PIO & ROS formulations after 48 hrs incubation with β -Amyloid.	229
8.1	Effect of amount of Stannous Chloride on radiolabeling efficiency of PIO and its nanoparticulate formulations with ^{99m}Tc	253
8.2	Effect of amount of Stannous Chloride on radiolabeling efficiency of ROS and its nanoparticulate formulations with ^{99m}Tc	253
8.3	Effect of pH on radiolabelling efficiency of PIO and its nanoparticulate formulations with ^{99m}Tc	253
8.4	Effect of pH on radiolabelling efficiency of ROS and its nanoparticulate formulations with ^{99m}Tc	254
8.5	Effect of incubation time on radiolabelling efficiency of PIO and its nanoparticulate formulations with ^{99m}Tc	254
8.6	Effect of incubation time on radiolabelling efficiency of PIO and its nanoparticulate formulations with ^{99m}Tc	255
8.7	Biodistribution of PIO-D (Oral)	255
8.8	Biodistribution of PIO-S (nasal)	256
8.9	Biodistribution of PIO-NP (i.v.)	256
8.10	Biodistribution of Tf-PIO-NP (i.v.)	257
8.11	Biodistribution of ROS-S (Oral)	257
8.12	Biodistribution of ROS-S (nasal)	258
8.13	Biodistribution of ROS-S (i.v.)	258
8.14	Biodistribution of ROS-NP (i.v.)	259
8.15	Biodistribution of Tf-ROS-NP (i.v.)	259